drugset / Trial / NCT05720325
Dupilumab Effects Against Aeroallergen Challenge
Phase 2
Active not recruiting
88 enrolled
The University of Texas Health Science Center at San Antonio
National Institute of Allergy and Infectious Diseases (NIAID) · collabRegeneron Pharmaceuticals · collab
RandomizedParallel-groupDouble-blindBasic science
Summary
The trial involves two interventions: (i) exposure to HDM in the ACC and (ii) administration of dupilumab/placebo for dupilumab.
Timeline
- Start
- 2023-03-29
- Primary completion
- 2026-11
- Completion
- 2027-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dupilumab | Monoclonal antibody | — | — |